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Background: The aim of this study was to describe bilateral visual outcomes and the effect 
of incomplete follow-up after 3 years of ranibizumab therapy for neovascular age-related 
macular degeneration. Secondarily, the demands on service provision over a 3-year period 
were described.
Methods: Data on visual acuity, hospital visits, and injections were collected over 36 months 
on consecutive patients commencing treatment over a 9-month period. Visual outcome was 
determined for 1) all patients, using last observation carried forward for missed visits due to 
early discontinuation and 2) only those patients completing full 36-month follow-up.
Results: Over 3 years, 120 patients cumulatively attended hospital for 1,823 noninjection visits 
and 1,365 injection visits. A visual acuity loss of 15 letters (L) was experienced by 78.2% of 
patients. For all patients (n=120), there was a mean loss of 1.68 L using last observation carried 
forward for missing values. Excluding five patients who died and 30 who discontinued follow-up, 
mean gain was 1.47 L. In bilateral cases, final acuity was on average 9 L better in second eyes 
compared to first eyes. Also, 91% of better-seeing eyes continued to be the better-seeing eye.
Conclusion: We have demonstrated our approach to describing the long-term service provision 
and visual outcomes of ranibizumab therapy for neovascular age-related macular degeneration 
in a consecutive cohort of patients. Although there was a heavy burden with very frequent 
injections and clinic visits, patients can expect a good level of visual stability and a very high 
chance of maintaining their better-seeing eye for up to 3 years.
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Introduction
In the National Health Service of the UK, ranibizumab (Lucentis®; Genentech, 
Inc., South San Francisco, CA, USA) monotherapy was recommended for patients 
with neovascular age-related macular degeneration (NV-AMD) by the National 
Institute of Clinical Excellence (NICE) in August 2008.1 The efficacy and safety of 
ranibizumab has been established by well-designed studies with endpoint analyses 
at 12 or 24 months.2–6 There is evidence to show that the initial treatment benefit can 
be maintained for longer periods of between 3 to 7 years from the first treatment,7–11 but 
due to the high dropout rate in almost all published long-term studies and the potential 
selection bias in prospective clinical trial extension studies, it can be difficult to demon-
strate the true, long-term treatment benefits and the burden of repeated injections over 
periods of 3 years or longer. The National Health Service setting in the UK is ideal for 
evaluating such parameters in a population that is uniformly managed, as up until very 
recently, ranibizumab has been used almost exclusively for NV-AMD, and decisions on 
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retreatment are not influenced by patients’ ability to pay. Our 
primary objective was to provide an  accurate description of 
visual outcomes in a consecutive and representative cohort of 
patients 3 years after  commencing ranibizumab therapy, tak-
ing into account the impact of incomplete follow-up on esti-
mates of visual acuity outcomes.  Secondary objectives were 
to describe the involvement of fellow eyes, maintenance of 
vision in better-seeing eyes, and the utilization of resources in 
terms of the number of injection and noninjection visits. It is 
envisaged that this unique report can be of value to clinicians, 
commissioners, and managers in highlighting the importance 
of accurate accountability of patient follow-up for the purpose 
of future audit comparisons and benchmarking.
Materials and methods
setting
Patients from a catchment population of about 850,000 sus-
pected of having NV-AMD were referred to a single-site, 
fast track, treatment service for logMAR visual acuity test, 
biomicroscopy, optical coherence tomography (OCT), 
and fluorescein angiography (FA) +/− indocyanine green 
angiography if there were clinical features of polypoidal 
vasculopathy. Confirmation of NV-AMD was based on 
presence of drusen or age-related changes in the retinal epi-
thelium on OCT and late-phase leakage on FA of subfoveal 
choroidal neovascularization with either classic, occult, or 
retinal angiomatous proliferative components. Eyes with 
NV-AMD and visual acuity of 6/12 to 6/96 were considered 
to satisfy the NICE guidance criteria1 and would receive a 
loading dose of three injections followed by retreatment 
on a pro re nata basis. Using a two-stop model, repeat 
injections were scheduled shortly after  monitoring visits 
if lesions were found to be active. As much as possible, 
monitoring visits were scheduled every month. A treat and 
extend regimen was not practiced in our department.
Retreatment decision was OCT-guided and was performed 
until no further reduction in intra or subretinal fluid could be 
achieved. In accordance with retreatment protocols used in 
earlier ranibizumab pro re nata studies such as the PRONTO 
(Prospective optical coherence tomography imaging of 
patients with neovascular AMD treated with intraocular 
ranibizumab) study,12 we did not specifically continue repeat 
injections to attempt to resolve pigment epithelial detach-
ments which were not associated with presence of subretinal 
or intraretinal fluid on OCT. Patients could be discharged from 
follow-up in the treatment program if they had not required 
retreatment in over 12 months or if it was felt that benefit 
could not be gained due to extensive macular damage.
Patient selection and data analysis
In line with our hospital policy, ethics committee approval 
for retrospective data collection studies was not required. 
Consecutive patients entering the treatment program between 
April 1, 2009 and December 31, 2009 were identified from 
an accurate injection database.
Patients were excluded from this survey if they had no 
follow-up after baseline injection or were recruited into a 
clinical trial. Eyes were excluded if they had any photody-
namic therapy (PDT), lesions secondary to non-AMD causes, 
serous detachments of pigment epithelium, peripapillary 
lesion, or choroidal polyps.
Data were collected on patients’ age and sex,  laterality of 
treatment, lesion type, visual acuities, central retinal thick-
ness (CRT), and number of FAs, OCTs, and treatment and 
nontreatment visits up to or nearest to month 36 or the final 
visit if follow-up was discontinued early. The reason for 
discontinuation was noted for each case.
First-treated eyes were defined as any eye treated at base-
line (both eyes were included if they were simultaneously 
treated at baseline). Treated second, fellow eyes were defined 
as any eye treated at subsequent visits to the first injection 
visit. Visual outcome data were determined at baseline and at 
yearly time points in terms of mean levels (number of Early 
Treatment Diabetic Retinopathy Study letters, [L]), mean 
change, proportions who gained and lost 15 L, and propor-
tions in strata of 25 L, 25–50 L, 50–75 L, and 75 L. Last 
observation carried forward (LOCF) was used for missing 
values for those patients who had not died but were dis-
charged early (full-analysis set).
To provide an indicator of overall visual outcomes at each 
time point, visual acuities were described by firstly analyzing 
all treated first and second eyes together and secondly by 
describing the visual outcomes in second eyes only.
To demonstrate the effect of using LOCF on reporting 
visual outcomes in real-world studies, where single samples 
or cohorts are used, we analyzed visual outcomes three times 
using different analysis sets. The first set was the per-protocol 
set, which contained patients who had full 3 year follow-up. 
The second set was the LOCF set, which contained patients 
who had not died but did not complete 3 year follow-up, and 
a third, full-analysis set, containing all patients. Values of 
visual outcomes over 3 years in these three analysis sets were 
tabulated for cross comparison without statistical testing to 
demonstrate the effects of using and not using LOCF.
To evaluate the impact of treatment on overall visual func-
tion, we compared the visual acuities at month 36 of treated 
and untreated eyes, and also determined the  proportion of 
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patients who had maintenance of vision in their better-seeing 
treated eyes.
Finally, to evaluate the anatomical effect of treatment, 
CRT values were compared between baseline and yearly 
time points and final visits in first-treated eyes.
Results
Patients, eyes, visits, injections,  
and follow-up
Over 9 months, 150 patients were identified, of whom 
22 patients entered a clinical trial (IVAN [Inhibition of VEGF 
in age-related choroidal neovascularization] study),5 and 
another eight patients were excluded from analysis due to the 
following reasons: 1) lack of any follow-up after first injection 
(three), 2) prior PDT (two), 3) pathological myopia (two), 
and 4) peripapillary choroidal neovascularization (one). Of 
the remaining 120 patients, mean age ± SD (standard devia-
tion) was 81.76±6.71 (range: 65–95) years, and 75 (62.5%) 
were female. At baseline, all 120 patients had an OCT 
scan, 112 (93%) had FA, and four (3%) had indocyanine green 
angiography. The lesion types were occult 67/120 (56%), 
classic containing 46/120 (38%), and retinal angiomatous 
proliferative 7/120 (6%). One hundred and seventeen had 
at least 1 year follow-up, 107 had at least 2 year follow-up, 
and 85 had at least 3 year follow-up. The data collection period 
covered a total of 1,823 noninjection visits and 1,365  injection 
visits in our two-stop system (mean of 15.33 injections per 
patient, six in the first year, four in the second year, and four in 
the third year. Bilateral involvement occurred in four patients 
from baseline and another 14 patients required injections to 
second fellow eyes during follow-up. Therefore, we collected 
data on 124 first eyes, 14 second fellow eyes, and 102 untreated 
eyes. Out of 120 patients with 124 first-treated eyes receiving 
injections at baseline (full-analysis set), five died and 30 did 
not complete 3 year follow-up, but 89 first study treated 
eyes of 85 patients (71%) did complete 3 year follow-up 
( per-protocol set). Table 1 shows the numbers of patients, 
eyes, treatment visits, nontreatment visits, and discontinua-
tions and their reasons.
Visual outcome
Visual outcomes for all treated eyes at each yearly time point 
are shown in Table 2. Baseline mean visual acuity was 52.24 L 
(SD ±14.69 L). At 36 months mean visual acuity was 51.01 L 
(SD ±19.46 L); mean change was −1.68 L (SD ±17.76 L). 
Proportion of eyes with 15 L loss was 78.2%, proportion 
of eyes with 15 L gain was 16.80%, proportion of treated 
eyes with 75 L was 10.08%, and proportion with 25 L 
was 13.44%. The percentage of patients in the four visual 
acuity strata at various time points for all patients complet-
ing 3 year follow-up are shown in Figure 1.
During the study period, 14 patients had treatment 
to second fellow eyes. These 14 eyes had mean baseline 
visual acuity of 59.28 L (SD ±15.07 L), which was better 
than first-treated eyes, indicating earlier presentation or 
diagnosis. By the time the first eyes had reached month 36, 
Table 1 numbers of patients’ eyes exposed to treatment and follow-up
n=120 Year 1 
0–12 months
Year 2 
13–24 months
Year 3 
25–36 months
number died =5 1 1 3
number of patients in full-analysis set 119 118 115
number lost to follow-up =30 2 9 19
reasons for drop outs F (n=2) F (n=1)
D (n=1)
i (n=7)
F (n=1)
D (n=7)
i ( n=10)
T (n=1)
number of patients remaining at end of year 117 107 85
number of second eyes commencing treatment 13 18 18
Number of first and second eyes actively treated in program 130 125 103
Mean number of total visits (range) 12.30 (7–18) 10.61 (3–18) 11.47 (1–17)
Mean number of injection visits (range) 5.87 (1–11) 4.06 (0–10) 4.21 (0–11)
Mean number of review visits (range) 6.42 (3–11) 6.54 (2–12) 7.25 (1–13)
Per-protocol set 85 85 85
Mean number of total visits (range) 12.87 (9–18) 11.47 (3–18) 11.47 (1–17)
Mean number of injection visits (range) 6.42 (1–11) 4.69 (0–10) 4.21 (0–11)
Mean number of review visits (range) 6.44 (3–11) 6.77 (2–10) 7.25 (1–13)
Abbreviations: D, discharged due to no recurrence 1 year; F, failed to attend; I, irreversible macular damage due to fibrosis or retinal pigment epithelial rip; T, transferred 
to other unit.
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Table 2 Details of visual outcomes in all treated eyes
Year 1 Year 2 Year 3
Number of patients 119 118 115
number of treated eyes 123 (4 bilateral  
from baseline included)
122 119 (lOCF in 34 eyes)
Baseline Va 52.24±14.69 52.44±14.60 52.89±14.63
Mean Va at end of year 51.01±19.46 49.74±21.18 51.15±21.09
Mean change in Va from baseline −1.34±15.34 −2.35±17.35 −1.68±17.76
Percentage with 15 l loss 84.56 80.33 78.2
Percentage with 15 l gain 13 12.29 16.80
Percentage with 25 l 13.82 13.11 13.44
Percentage with 75 l 9.75 9.01 10.08
Subset of second eyes affected at end of year 9 14 14
Baseline Va 64±12.14 61±13.16 59.28±15.07
Mean Va at end of year 66.44±15.39 62.85±11.71 56.92±16.55
Mean change in Va from baseline 2.44±6.48 2±11.01 −2.35±11.64
Abbreviations: lOCF, last observation carried forward; Va, visual acuity; l, early Treatment Diabetic retinopathy study letters.
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Figure 1 Distribution of patients who have completed three year follow-up across four strata of visual acuity at yearly time points.
the final mean visual acuity of second eyes was 56.92 L 
(SD ±16.55 L) (mean change −2.35±11.64 L), which was 
approximately 9 L better than the mean 36 month acuity of 
first eyes. The outcomes at yearly time points of second eyes 
are shown in Table 2.
Table 3 illustrates the different visual outcomes at the 
end of year 3 obtained by using the per-protocol set or the 
full-analysis set. In the full-analysis set, LOCF was used for 
missing values from 30 eyes of 30 patients who discontinued 
follow-up. These eyes had poorer outcome, with a mean loss 
of visual acuity from baseline to end of year 3 of 11.03 L 
(SD ±20.29 L, range −63 L to 21 L). One patient had visual 
loss of 63 L after the third injection. Removing this outlier 
made minimal difference to the overall estimate of mean 
change in visual acuity at month 36 (−1.16±15.54 L). In 
the per-protocol set, when only the 89 eyes of 85 patients 
who had full 3 years of follow-up were included, the visual 
outcomes appeared better. The mean visual acuity improved 
by 1.47 L (SD ±15.60 L) from 53.75 L (SD ±13.59 L) at base-
line to 55.14 (SD ±17.97 L) at the end of year 3.  Outcomes 
Clinical Ophthalmology 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
721
Three years of ranibizumab for nV-aMD
in terms of proportions were also better: the proportion 
with 15 L loss was 84.26%, the proportion with 15 L 
gain was 19.10%, the proportion with 50 L was 65%, 
the proportion with 75 L was 10%, and the proportion 
with 25 L was only 4.49%.
Prognosis of better-seeing eyes  
and never-treated fellow eyes
In the per-protocol set with complete 3 year follow-up, 89 eyes 
of 85 patients were treated at baseline, and 81 fellow 
eyes never received treatment. The treated eyes were the 
better-seeing eyes for 43 (51%) of these patients at base-
line, and with treatment, remained the better-seeing eyes 
in 39 (91%) patients after 3 years. Of the 81 never-treated 
eyes, 67 remained untreated up to the end of year 3. The mean 
acuity of these never-treated eyes changed from 44.86 L 
to 43.48 L over 3 years.
Central retinal thickness
In first-treated eyes reaching month 36 follow-up, the CRT 
values at baseline were 423.30±115.38 µm and then reduced 
to 325.01±79.10 µm, 331.74±88.31 µm, and 325.08±97.62 µm 
at 12, 24, and 36 months, respectively.
Discussion
We were able to reliably identify and complete abstraction 
of data from case notes of a consecutive cohort of patients 
from the baseline visit (first ranibizumab treatment) until 
a time point when they should have completed 3 years of 
follow-up. In total, 120 consecutive patients commenced 
therapy during a 9-month period, and 35 patients discontin-
ued follow-up giving a 3-year attrition rate of 29% for our 
service. Only 3% required bilateral treatment from baseline, 
and 12% required second eye treatment within 3 years. Over 
the course of 3 years, this cohort of patients made a total 
of 3,188 visits and received 1,365 injections. From our data 
on service provision, we can deduce that for a  population 
of 1 million, approximately 2,446 injections would be 
required in a 3-year period. However, if fixed monthly injec-
tions were given, 7,282 injections would be required over 
a 3-year period for the new cases arising each year from a 
population of 1 million. With the introduction of newer agents 
for NV-AMD such as aflibercept, which may require less 
frequent injections,13,14 future audits may confirm a reduced 
burden on injection visits.
The treatment benefit for our cohort of patients 
after 3 years was visual stability. Overall, their mean change 
in acuity was only −1.16 L, and 78.2% of patients lost 15 L. 
To our knowledge, this is the first study to estimate the 
visual benefit to patients in terms of maintenance of the 
better-seeing eye with therapy in treatment-naive patients. 
In this cohort, as many as 51% of patients only received 
ranibizumab therapy in the better-seeing eye. Of these, 91% 
of patients continued to have better vision in their treated 
eyes after 3 years.
Our visual outcomes after 3 years are broadly comparable 
to those described in other “real-world” outcomes studies from 
the UK8,9 and other countries.11,15,16 Several methodological 
differences between these real-world studies are worth noting 
when comparing visual outcomes. Some studies9,11 converted 
Snellen visual acuities into logMAR scale, which has a ten-
dency to over-estimate acuity, especially at the lower levels. 
A few studies had patients with variable follow-up dura-
tion and either excluded those with incomplete follow-up, 
 making the sample unrepresentative at baseline,8 or did not 
take into account the impact of attrition when calculating 
change in visual acuity from baseline, such that the baseline 
mean acuity was calculated in a larger sample, and the final 
mean acuity was calculated from a smaller sample.9 In this 
study, we found that the exclusion of discontinued patients 
from the analysis can have a sizeable impact on visual out-
come parameters. This negative impact of applying LOCF 
was also reported recently by Frennesson and Nilsson16 and 
Rasmussen et al.11 Excluding discontinued patients from the 
Table 3 Visual outcome parameters from baseline to end of year 3 in three different analysis sets
Per-protocol  
set n=89
LOCF  
set n=30
Full analysis set  
(per protocol + LOCF) 
n=119
Va at baseline mean ± sD letters 53.75±13.59 50.33±17.10 52.89±14.63
Va at end of year 3 mean ± sD letters 55.14±17.97 39.3±24.86 51.15±21.09
Mean Va change ± sD letters +1.47±15.60 −11.03±20.29 −1.68±17.76
15 letter loss (%) 84.26 60 78.2
15 letter loss (%) 15.74 40 21.8
15 letter gain (%) 19.10 10 16.80
Abbreviations: lOCF, last observation carried forward; sD, standard deviation; Va, visual acuity.
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analysis and not applying LOCF can lead to overestimation of 
visual outcomes, as the commonest reason for discontinuing 
patients from follow-up was the development of end stage, 
“stable,” macular damage.11,15 Studies which had a very high 
percentage of missing data or discharge rate can be difficult to 
interpret. Rasmussen et al11 reported a mean acuity of change 
from 0.24 L (n=600 eyes) to 0.18 L (n=192 eyes) after 4 years, 
and Ross et al17 reported an attrition from 406 eyes 
at 12 months to 198 eyes at 24 months due to insufficient 
follow-up data entry. These high attrition rates can obviously 
have a random and unpredictable impact on the estimation of 
visual outcome, even when LOCF is applied. Furthermore, 
it is important to note if a study had included patients who 
had prior PDT,11 as this can give rise to an underestimation 
of visual benefit from ranibizumab therapy.
The major strength of real-world studies is that they rep-
resent the true population that we treat in everyday settings. 
Randomized clinical trials are very good for demonstrating 
the maximum efficacy of a therapy but may not be representa-
tive of the general population due to the inevitable selection 
bias caused by the tendency to recruit patients with fewer 
comorbidities for clinical trials. In our study, we have been 
careful to be representative by analyzing consecutive patients 
and not excluding anyone from the baseline analysis because 
of subsequent incomplete follow-up data availability. We 
accounted for every patient that was discontinued and applied 
LOCF in the full-analysis set. Missing data was therefore due 
purely to discontinued patients due to our discontinuation 
policies and not due to incomplete data entry. This ensured 
a high level of representativeness of our study population. 
We had an attrition rate of 30% over 3 years, which can be 
tolerated when using the LOCF method.18,19 For comparing 
visual outcomes between sites, it is important to ensure the 
representativeness of the sample and the inclusion of discon-
tinued patients in the final analysis using LOCF.
Like other real-world studies, our study also did not 
have best corrected visual acuity. When comparing with 
levels achieved in clinical trials, some allowance has to be 
made for an underestimation. Our sample size was also quite 
small as the study period we selected to give us 36 months of 
follow–up coincided with the time when we were recruiting 
into a clinical trial. As the inclusion criteria of the IVAN 
study was based on NICE guidelines, we do not think this 
created a selection bias for this study. A larger sample would 
have helped to generate narrower SDs on the estimates of 
visual acuity outcomes.
Rasmussen et al11 reexamined patients who had previously 
been discontinued from therapy due to disease  inactivity and 
found that many patients continued to decline. This means 
that our method of applying LOCF to those we discharged 
may also give rise to an overestimation but probably not as 
much as would be caused by not applying LOCF and exclud-
ing them from analysis.
In conclusion, we have tried to provide an accurate evi-
dence base of not only the visual benefit that can be gained 
from ranibizumab therapy by patients with NV-AMD over 
a 3-year period but also, for the first time, describe the actual 
burden of therapy in terms of hospital visits and injections for 
our patients. We surveyed a consecutive and representative 
sample of patients and took into account the impact of early 
discontinuation from follow-up on estimates of visual out-
comes. For the first time, to our knowledge, we demonstrated 
a 91% rate of maintenance of stability in the better-seeing eye 
in the most desperate group of patients who were receiving 
unilateral treatment to their better-seeing eyes. We believe 
outcomes reported in real-world studies can be useful to 
emphasize the burden of disease and also to demonstrate the 
true benefit of therapy for patients outside the near-perfect 
world of the clinical trial setting. We also highlighted several 
pitfalls and inaccuracies that can occur when collecting data 
and auditing services and also in comparing visual and other 
outcome parameters for purposes of benchmarking, which 
may become increasingly important if we are to enter an era of 
making our clinical outcomes available for public scrutiny.20
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